← All companies

KLRA

Kailera Therapeutics, Inc.

KLRA Nasdaq Pharmaceutical Preparations EDGAR ↗

$17.32

+0.27 +1.58%

Key statistics

from XBRL data in SEC filings

Market cap

$2.24B

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$112M

Total assets

$625M

Gross margin

—

52-week range

$16.39 – $28.23

Recent SEC filings

40 most recent

Annual, quarterly & current reports

10-Q Quarter ended 2026-03-31 May 26, 2026 8-K Results of operations (earnings release) May 26, 2026 8-K Amended charter or bylaws; Other events Apr 20, 2026

Other filings

4 Jul 8, 2026 3 Jul 8, 2026 4 Jun 11, 2026 SCHEDULE 13D Apr 23, 2026 SCHEDULE 13D Apr 23, 2026 4 Apr 22, 2026 4 OWNERSHIP DOCUMENT Apr 22, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 4 Apr 20, 2026 424B4 Apr 17, 2026 S-8 Apr 17, 2026 EFFECT Apr 16, 2026 3 OWNERSHIP DOCUMENT Apr 16, 2026 3 Apr 16, 2026 3 Apr 16, 2026 3 Apr 16, 2026 3 Apr 16, 2026 3 Apr 16, 2026 3 Apr 16, 2026 3 Apr 16, 2026 3 Apr 16, 2026 3 Apr 16, 2026 3 Apr 16, 2026 3 Apr 16, 2026